News and Announcements

ImmuneWorks is a sponsor of the Pulmonary Fibrosis Foundation’s inaugural “IPF Summit 2011: From Bench to Bedside” scientific conference. Read More

Biotechnology firm, ImmuneWorks, is ramping up efforts to support National Pulmonary Fibrosis (PF) Awareness Week (September 18-24). IPF is one of the most fatal, yet publicly unrecognized, diseases claiming more and more lives every year. Read More

ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound. Read More

Lung Rx, LLC, a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), announced today that it has entered into a Development Agreement with ImmuneWorks, Inc. to pursue development of ImmuneWorks’ lead compound, IW001, a purified bovine Type V Collagen oral solution for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in patients receiving lung transplant. The parties expect to commence human clinical testing in 2010. In November 2009, the U.S. Food and Drug Administration granted orphan drug exclusivity to IW001. Read More

ImmuneWorks announces that the U.S. Food and Drug Administration (FDA) recently designated IW001 (bovine Type V Collagen oral solution) as an Orphan Drug. Orphan drugs are those drugs that are intended to be used in populations smaller than 200,000 patients in the United States. Read More

Each year more than 40,000 people die of idiopathic pulmonary fibrosis (IPF), a devastating lung disease – leading to the same number of deaths as breast cancer. Currently, there is no effective treatment for the disease. However, ImmuneWorks, an Indianapolis-based biotechnology company committed to developing effective treatments for serious lung diseases, is developing a safe and effective treatment for IPF patients. Read More

ImmuneWorks, Inc is pleased to announce that BioWorld, a leading publication covering the global biotechnology sector included the Indianapolis-based company in its annual listing of leading innovations, Innovations in Biotechnology 2008. “We are gratified that the global biotechnology community recognizes the innovative science underlying ImmuneWorks. Most importantly, we are working aggressively to translate the science that BioWorld recognized into real world treatments for such a deadly disease as Idiopathic Pulmonary Fibrosis,” stated David S. Wilkes, MD ImmuneWorks founder and Chief Science Officer. Read More

Local biotechnology startup ImmuneWorks LLC is attempting to develop treatment for autoimmune diseases in human lungs. Life science industry veteran Wade Lange became its CEO this summer. Read More

When Teresa Geiger attended a lung disease conference five years ago, she could count on one hand the number of meetings dedicated to something called idiopathic pulmonary fibrosis. Read More

Founded less than two years ago to exploit a discovery by researchers at Indiana University on the role of Type V collagen in lung transplant rejection, start-up ImmuneWorks LLC is ready to start pushing its first program into the clinic aimed at idiopathic pulmonary fibrosis. Read More

A startup firm using Indiana University medical research to treat a fatal lung disease is raising money for clinical trials and has recruited a prominent life sciences veteran to lead the effort. Read More